Objective-To explore the effect of the Heerlen polymorphism and C4b-binding protein (C4BP) on protein S catabolism in vitro and in vivo. Methods and Results-Radiolabeled protein S was efficiently bound and intracellularly degraded by THP-1 macrophages, and both processes were strongly reduced in the presence of the protein S-carrier protein C4BP. To test whether C4BP displays a similar protective effect in vivo, survival experiments were performed in mice. In the absence of C4BP, radiolabeled human protein S disappeared in a biphasic manner (mean residence time [MRT] 2 hours). However, the presence of C4BP resulted in a 4-fold prolonged survival of protein S (MRT 8 hours; PϽ0.0001). We also applied this experimental model to recombinant protein S-Heerlen, a naturally occurring variant that contains a Ser460Pro substitution. These clearance experiments revealed a strongly decreased survival of recombinant protein S-S460P (MRT 0.6 hours; Pϭ0.021), which could be compensated partially by C4BP (MRT 1.4 hours; Pϭ0.012 compared with protein S-S460P).
P rotein S circulates in plasma at a concentration of 0.3 mol/L, although this value may vary between individuals. 1 Only 30% to 40% of protein S circulates in a free form, whereas the remaining part is in complex with C4b-binding protein (C4BP). 2 Various isoforms of C4BP exist, and only those that contain the ␤-chain (ie, C4BP␣␤) bind protein S. 3 Because the C4BP␣␤ plasma concentration is lower than that of protein S, the molar excess of protein S over C4BP␣␤ determines the amount of free protein S.
The function of protein S relates to various physiological processes, including the clearance of apoptotic cells and neuronal protection during ischemic/hypoxic injury. 4 -6 However, protein S is originally known from its role in the anticoagulant process, 7, 8 in which it functions as a cofactor for activated protein C (APC). 9, 10 In addition, protein S may downregulate the coagulation pathway independently of APC. 11, 12 The notion that deficiencies in protein S are associated with an increased thrombotic tendency 13, 14 demonstrates that appropriate plasma levels of protein S are needed to maintain the hemostatic balance.
Two categories of protein S deficiency can be distinguished: 15 (1) qualitative defects (type II deficiency), and (2) quantitative defects (type I or III deficiency). Type I deficiency refers to a parallel reduction of total and free protein S. Type III deficiency is characterized by low levels of free protein S but normal levels of total protein S. However, both types of quantitative deficiencies often occur within the same family, 1 and more detailed analysis revealed that increased levels of total protein S as seen in type III coincide with an age-dependent increase in protein S levels. 16 Quantitative deficiencies of protein S may obviously originate from null alleles, but also, missense mutations can lead to reduced protein S levels. 15 Some of these missense mutations result in impaired secretion of the protein. [17] [18] [19] However, not all amino acid replacements associated with low levels of protein S associate with abnormal secretion. An example hereof is protein S-Heerlen, which contains a Ser to Pro replacement at position 460. 20 This substitution results in loss of N-linked glycosylation at position Asn458. Protein S-Heerlen is found in Ϸ0.5% of the population 20 and is associated with reduced levels of free protein S in heterozygous or homozygous individuals. 21, 22 Expression studies demonstrated that recombinant protein S-S460P is normally secreted, 21 indicating that other mechanisms should be in-volved that explain the quantitative deficiency of protein S-Heerlen. Possible mechanisms that have been proposed include increased affinity for C4BP␣␤ or multivalency of C4BP␣␤ for this variant. 23 However, protein S-S460P and protein S were similar in their interaction with C4BP␣␤ in various other reports. 20, 21, 24, 25 The notion that protein S-S460P is similar to wild-type (wt)-protein S in terms of secretion efficiency and binding to C4BP␣␤ prompted us to investigate the previously proposed hypothesis that protein S-Heerlen is cleared from the circulation more rapidly than normal protein S (Dr R.M. Bertina, XVI ISTH Congress, Florence, Italy, 1997). Therefore, a mouse model was used to investigate the in vivo survival of wt-protein S and recombinant protein S-S460P in the presence and absence of C4BP␣␤.
Methods

Mice
The mice used in the present study were on a C57BL/6J background and were used between 8 and 12 weeks of age. Housing and experiments were done as recommended by French regulations and the experimental guidelines of the European Community.
Reagents and Proteins
Chloroquine was from Serva. Methyl-␤-cyclodextrin (M␤CD) was from Sigma-Aldrich. C4BP␣␤ was prepared from plasma via barium-citrate absorption and immunoaffinity chromatography to homogeneity (see supplemental data, available online at http://atvb. ahajournals.org). No protein S antigen could be detected in these C4BP␣␤ preparations in an immunosorbent assay, whereas the ability to bind protein S was fully retained. Purification of recombinant C4BP␣, recombinant wt-protein S, and recombinant protein S-S460P has been described previously 24, 26, 27 (see also online supplemental data).
Radiolabeling of Protein S
Purified wt-protein S or protein S-S460P was labeled with Na 125 I (Amersham Biosciences Inc) using the IODO-GEN method 28 (online supplemental data). Final preparations had specific activities varying between 1.4ϫ10 6 and 2.2ϫ10 6 cpm/g protein (nϭ2 to 10), whereas free iodine was routinely Ͻ6%. This method to radiolabel protein S does not affect C4BP␣␤ binding capacity (data not shown) and APC cofactor activity. 28
Cellular Binding, Internalization, and Degradation Experiments
Cellular binding and degradation experiments were performed using human THP-1 cells (ATCC TIB-202). These cells have been used previously to study the role of protein S in the engulfment of apoptotic cells by macrophages. 29 Binding, internalization, and degradation of protein S by THP-1 macrophages were investigated using standard cell biological methods, which are described in detail in the online supplemental data.
Clearance and Biodistribution of Protein S in Mice
Normal C57BL/6J mice were injected intravenously with radiolabeled protein S or protein S-S460P (5 g per mouse, corresponding to 9ϫ10 6 cpm per mouse) in the presence or absence of a 2-fold molar excess C4BP␣␤, diluted in PBS containing 3% bovine albumin. To facilitate complex formation, protein S (0.3 mol/L) and C4BP␣␤ (0.6 mol/L) were incubated for 45 minutes before injection. Because the concentration of both proteins is Ͼ300-fold above the K D value (Ͻ1 nmol/L), 24 these conditions result in Ͼ95% of protein S being in complex with C4BP␣␤. Furthermore, concentrations of C4BP␣␤ were chosen to be Ն4-fold below those that saturate the clearance system. At different time points after injection (3, 15 , and 30 minutes, and 1, 2, and 4 hours), mice were anesthetized with tribromoethanol (0.15 mL/10 g of body weight), and blood was collected by eye bleed. Subsequently, plasma was prepared as described 30 and analyzed for the presence of radioactivity. After bleeding, mice were euthanized, and various organs (heart, lungs, liver, spleen, stomach, kidneys, and left upper leg) were collected, which were analyzed for the amount of radioactivity. Three mice were used for each time point.
Data Analysis and Statistics
Data of in vivo survival experiments were fitted to a biexponential equation as described previously 31 to allow calculation of the parameters mean residence time (MRT), t 1/2 ␣, and t 1/2 ␤. Statistical analyses were performed by Student's unpaired t test using the GraphPad InStat program (GraphPad Instat version 3.0 for Windows; GraphPad Software).
Results
Binding of Protein S to THP-1 Macrophages
Recently, protein S has been reported to mediate the engulfment of apoptotic cells by macrophages. 4 Here, we tested whether human THP-1 macrophages are able to bind and deliver protein S to the intracellular degradation pathway. Binding was assessed by incubating radiolabeled protein S (0 to 0.52 mol/L) with THP-1 macrophages for 2 hours at 4°C. Protein S bound to THP-1 macrophages in a saturable and dose-dependent manner, and half-maximal binding was at a concentration of 0.11Ϯ0.04 mol/L ( Figure 1A ). The number of binding sites was found to be 4.3Ϯ0.5ϫ10 5 per cell. Specificity of binding was addressed in 2 types of control experiments. First, labeled and unlabeled protein S were applied to the cells at different ratios while maintaining total protein S concentration constant. A linear decrease in binding of radiolabeled protein S was observed (slope Ϫ1.0Ϯ0.1; Y-intercept 105Ϯ3), indicating that labeled and unlabeled protein S bind THP-1 macrophages similarly. Second, binding of radiolabeled protein S was reduced Ͼ90% by a 100-fold excess of unlabeled protein S ( Figure 1A , inset).
Internalization and Degradation of Protein S
Subsequently, we tested whether binding was followed by transport of protein S to the intracellular degradation pathway. Radiolabeled protein S (0.13 mol/L) was incubated with macrophages (1 hour at 4°C) to allow surface binding. After washing, cells were put at 37°C to initiate internalization. Cell surface-bound protein S had disappeared by Ͼ90% within 40 minutes ( Figure 1B) . Simultaneously, the amount of internalized protein S had increased and reached a maximum after 40 minutes, which was followed by a gradual decline. Degradation was examined by monitoring the formation of trichloroacetic acid-soluble fragments on incubation with radiolabeled protein S (0.13 mol/L). In time, increased levels of degradation products were observed ( Figure 1C ). Degradation was markedly reduced in the presence of M␤CD (interferes with caveolae-and clathrin-dependent endocytosis) or the lysosomal inhibitor chloroquine ( Figure 1C ). Together, these data demonstrate that human macrophages can bind and transport protein S to their intracellular degradation pathway.
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C4BP␣␤ Partially Inhibits Macrophage-Dependent Protein S Degradation
Because part of protein S circulates in complex with C4BP␣␤, cellular uptake of protein S was tested in the presence of its carrier protein. When assessed for binding to THP-1 macrophages, a 5-fold excess of C4BP␣␤ reduced binding by 60%, whereas the nonbinding counterpart C4BP␣ was unable to reduce binding (Figure 2A ). A similar effect was observed when protein S degradation was monitored. Whereas C4BP␣ did not inhibit degradation, C4BP␣␤ reduced degradation 4-to 5-fold ( Figure 2B ). These levels were reduced to a similar extent as observed for the degradation inhibitors M␤CD and chloroquine. Apparently, complex formation with C4BP␣␤ reduces the cellular uptake of protein S.
Biphasic Disappearance of Protein S From Plasma
In view of the in vitro effect of C4BP␣␤ on the cellular uptake of protein S, we considered the possibility that C4BP␣␤ exerts a similar effect in vivo. To test this possibility, we addressed the survival of protein S in a mouse-model. Murine C4BP lacks the ␤-chain, rendering this protein unable to bind protein S. This allowed us to use this model to directly examine the effect of human C4BP␣␤ on the survival of protein S. First, we evaluated the disappearance of protein S from plasma by administering radiolabeled recombinant wtprotein S (5 g per mouse) to normal C57BL/6J mice by tail vein injection. Mice were then bled at indicated time points, and plasma was analyzed for residual activity. The recovery (3 minutes after injection) was 61.1Ϯ0.5% (nϭ3 mice; Table) . Graphic representation showed that the protein is cleared in a biphasic manner, with a rapid initial phase and a slow secondary phase ( Figure 3A ). Data analysis allowed calculation of the apparent half-lives, which were 3.6Ϯ2.9 minutes and 1.4Ϯ0.5 hours for the rapid and slow phase, respectively. The MRT was 1.9Ϯ0.6 hours (Table) .
Protein S Is Primarily Targeted to the Liver
In the same experiments, we also tested the biodistribution of protein S by collecting the various organs and measuring their content of radioactivity. Minor amounts of radioactivity (Ͻ3% of the amount injected) were found in heart, lungs, spleen, kidneys, and left upper leg during the full time course of the experiment (data not shown). In the stomach, similar low amounts were found shortly after injection, whereas some radioactivity (up to 7%) started to accumulate in this organ 1 hour after injection. With regard to the liver, 17.9Ϯ0.4% of the amount injected could be detected within 3 minutes after injection. This amount remained stable until 15 minutes (19Ϯ3%), followed by a sharp decline between 0.5 and 4 hours. Thus, intravenously administered protein S is mainly directed to the liver.
C4BP␣␤ Prolongs the In Vivo Survival of Protein S
To test the effect of C4BP␣␤ on the survival of protein S, both proteins were first preincubated in a 2:1 ratio before injection (see Methods). On intravenous application, the initial yield of protein S was significantly higher in the presence of C4BP␣␤ than in its absence (72% versus 61%; Pϭ0.048; Table) . Furthermore, protein S disappeared slower from plasma in the presence of C4BP␣␤, as illustrated by increased half-lives of both phases of the clearance process ( Figure 3B ; Table) . Indeed, the MRT was increased 4-fold Binding, internalization, and degradation of wt-protein S by THP-1 macrophages. A, THP-1 macrophages were incubated for 2 hours at 4°C with radiolabeled wt-protein S (0 to 0.5 mol/ L). Bound wt-protein S was determined as described in Methods and corrected for nonspecific binding in the absence of cells (routinely Ͻ15%). A, Inset, Binding of radiolabeled wt-protein S (0.13 mol/L) was assessed in the absence or presence of a 100-fold molar excess of unlabeled wt-protein S. B, THP-1 macrophages were incubated with radiolabeled wt-protein S for 1 hour at 4°C. After washing, cells were placed at 37°C to initiate internalization. At indicated time intervals, the amount of surface-bound (F) and internalized (E) protein S was determined as described in Methods. Plotted is the amount of radioactivity relative to the amount of surface-bound radioactivity at tϭ0 (100%). Data are corrected for the amount of radioactivity present in the absence of cells (Ͻ15%). C, THP-1 macrophages were incubated with radiolabeled wt-Protein S (0.13 mol/L) either in the absence (F) or presence of 10 mmol/L M␤CD (Ⅺ) or 0.1 mmol/L chloroquine (E) for 10 minutes at 37°C. After washing, incubation was continued at 37°C for indicated time intervals. The amount of degraded wt-protein S was determined as described in Methods and corrected for nonspecific degradation in the absence of cells (routinely Ͻ10%). Data represent meanϮSEM of 2 to 10 experiments performed in duplicate. from 1.9 to 7.8 hours (Pϭ0.0001). Corresponding with the slower clearance, lower amounts of radioactivity were found in the liver at 3 and 15 minutes after injection (14.4Ϯ0.9 versus 17.9Ϯ0.4% [Pϭ0.0035] and 11.7Ϯ3.9 versus 19.3Ϯ2.7% [Pϭ0.049] for the presence and absence of C4BP␣␤). In addition, a more gradual decline in the amount of radioactivity in the liver was observed in the presence of C4BP␣␤. Thus, C4BP␣␤ delays the liver-mediated clearance of protein S in our experimental model.
Increased Clearance of Protein S-S460P
To investigate whether clearance of protein S can be influenced by changes in amino acid sequence, we studied the in vivo survival of protein S-S460P. This mutant comprises a Ser460 to Pro replacement and is associated with reduced antigen levels. Purified recombinant protein S-S460P was 125 I-labeled and injected intravenously in the tail vein of normal C57BL/6J mice. At indicated time points, the mice were bled, and plasma was analyzed for the presence of residual radioactivity. The recovery after 3 minutes was 59.0Ϯ2.3% (nϭ3 mice; Table) . As for wt-protein S, protein S-S460P disappeared in a biphasic manner, although remarkably more rapidly than wt-protein S ( Figure 3C ). Indeed, t1/2␣ and t1/2␤ are reduced 2-to 3-fold for protein S-S460P compared with wt-protein S (Table) . Also, the calculated MRT was 3-fold shorter for the mutant compared with wt-protein S (Table) . The increased clearance was associated with a faster appearance of the mutant in the liver at 3 minutes and 15 minutes after injection ( 
C4BP␣␤ Partially Compensates the Increased Clearance Rate of Protein S-S460P
Because C4BP␣␤ reduces the clearance rate of wt-protein S, it was of further interest to investigate the effect of C4BP␣␤ on the in vivo survival of protein S-S460P. In preliminary experiments, the interaction between C4BP␣␤ and this particular mutant was examined using surface plasmon resonance analysis. As expected, these experiments revealed that the mutant was similar to wt-protein S with regard to C4BP binding in terms of association and dissociation rate constants. 24 Protein S-S460P was radiolabeled and subsequently incubated with a 2-fold molar excess of human C4BP␣␤ before intravenous injection. The initial recovery 3 minutes after injection was 61.2Ϯ6.4%, which is similar to the recovery of protein S-S460P in the absence of C4BP (Table) . However, the protein S-S460P/C4BP␣␤ complex disappeared less rapidly from the circulation compared with free protein S-S460P ( Figure 3D ). For instance, at the 15-minute time point, 44.5Ϯ1.4% protein S-S460P/C4BP␣␤ complex was present compared with 34.9Ϯ3.8% of protein S administered in the absence of C4BP␣␤ (Pϭ0.015). Calculation of the kinetic parameters revealed that t1/2␣, t1/2␤, and MRT were all increased in the presence of C4BP␣␤ (Table) . Thus, †P values for wt-protein S/C4BP␣␤ and protein S-S460P are relative to wt-protein S; ‡P values for protein S-S460P/C4BP␣␤ are relative to protein S-S460P. Figure 3 . Disappearance of wt-protein S or protein S-S460P from plasma in the presence or absence of C4BP␣␤. C57BL/6J mice were injected with radiolabeled wt-protein S or protein S-S460P (5 g per mouse; 1.8ϫ10 6 cpm/g protein) in the absence (A and C) or presence (B and D) of a 2-fold molar excess of C4BP␣␤ (preincubated 45 minutes before injection). Blood samples were taken at indicated time intervals, and the amount of residual radioactivity in plasma was measured. Plotted is the amount of residual radioactivity relative to the amount injected vs time after injection. The solid line is that obtained after fitting the experimental data to a biexponential equation, 31 the parameters of which are summarized in the Table. The the increased clearance rate of protein S-S460P is delayed by the presence of C4BP␣␤.
Pharmacokinetic Parameters Describing the Clearance of Recombinant wt-Protein S and Protein S-S460P in the Absence or Presence of C4BP␣␤
Discussion
Distortion of the balance between procoagulant and anticoagulant pathways can lead to bleeding or thrombotic complications. Such misbalance is often the result of concentrations of components that are too high or too low. For instance, low levels of protein S are associated with an increased thrombotic risk 13, 14 Low protein S levels may originate from impaired synthesis/secretion, increased clearance, or combinations thereof. Examples of mutations leading to impaired secretion have been described. [17] [18] [19] However, little is known about the protein S clearance mechanism and how this process is affected by variations in the protein S amino acid sequence or its carrier protein C4BP␣␤.
The possibility that C4BP␣␤ affects protein S clearance became apparent in our in vitro experiments regarding the cellular uptake of protein S. We observed that human THP-1 macrophages are able to bind and transport protein S to its intracellular degradation pathways (Figure 1 ). THP-1 macrophages comprise Ϸ4.3ϫ10 5 binding sites per cell, a number that is in between the amount of binding sites reported previously for bovine aortic endothelial cells (8.5ϫ10 4 sites per cell 32 ) and human umbilical vein endothelial cells (8.0ϫ10 5 sites/cell 28 ). Binding and intracellular delivery was markedly reduced in the presence of C4BP␣␤ (Figure 2 ). This effect is in line with the observation by Kask et al that C4BP␣␤ interferes with the protein S-dependent uptake of apoptotic cells by macrophages 29 and suggests that the C4BP␣␤-binding region (ie, the carboxyl-terminal sex hormone binding globulin-like domain) contributes to the interaction with macrophages. Indeed, preliminary experiments revealed that a recombinant fragment of this region indeed binds to macrophages, albeit with a 5-fold lower affinity (data not shown). However, the notion that C4BP␣␤ inhibits cellular uptake only partially points to the possibility that other parts also not covered by C4BP␣␤, such as the amino terminal Gla domain, can mediate cellular binding. Alternatively, the residual uptake may also be facilitated by lowdensity lipoprotein receptor-related protein, which is present in THP-1 macrophages. We reported previously that this receptor contributes to C4BP␣␤ catabolism in vitro and in vivo. 33 As to the behavior of protein S in vivo, we found that protein S disappeared in a biphasic manner, with an overall MRT of 1.9 hours (Figure 3 ; Table) . The relatively rapid disappearance from plasma went together with a rapid appearance of radioactivity in the liver (data not shown), suggesting that protein S is mainly directed to this organ. Little contribution of other organs to the uptake of protein S was observed, although in time, accumulation of radioactivity in the stomach was observed. Similar delayed accumulation of radioactivity in the stomach has been described for other proteins, such as von Willebrand factor (vWF) and insulin growth factor binding protein-3. 31, 34 In case of the latter, this accumulated radioactivity represents small, degraded peptides that are excreted from the liver and reabsorbed by the stomach. Given the time course by which radioactivity appears in liver and stomach, respectively, it seems conceivable that a similar mechanism applies to protein S.
The murine model was particularly useful to study the effect of C4BP␣␤ on protein S clearance for 2 reasons: (1) murine C4BP lacks the ␤-chain, which renders it unable to bind protein S; 35 and (2) murine protein S displays low affinity for human C4BP␣␤, which is mainly because of the presence of a Glu instead of a Gln at position 427 36, 37 . Thus, the complex between human protein S and human C4BP␣␤ is affected by their murine counterparts only to a minor extent, if any. The presence of C4BP␣␤ resulted in a 4-fold prolonged survival of protein S in the circulation and a delayed uptake in the liver (Figure 3 ; Table) . This demonstrates that C4BP␣␤ displays a similar protective effect in the in vivo mouse model compared with the in vitro system using human cells. Of interest, the disappearance of the C4BP␣␤/protein S complex mimicked that of C4BP␣␤ alone ( Figure 3B , inset), suggesting that clearance of the complex is merely mediated by C4BP␣␤. It should be noted that the half-life of the protein S/C4BP␣␤ complex in the mouse is shorter than the half-life of protein S in humans (8 hours compared with Ϸ40 hours based on the disappearance of the protein on warfarin treatment). Similar species-specific differences have been reported for numerous other proteins, including factor IX and vWF. Whereas the half-life of vWF in humans is Ϸ14 hours, its survival in mice is reduced 4-to 5-fold. 31 These differences in clearance rate are probably a reflection of the basal metabolic rate, which is increased in mice.
The protective effect of C4BP␣␤ seems to resemble the effect of vWF on the in vivo survival of coagulation factor VIII because the absence of vWF results in increased clearance of factor VIII. 38 It is tempting to extrapolate our data obtained with in vitro experiments using human THP-1 cells, and the murine in vivo experiments to the human situation in that C4BP␣␤ interferes with protein S clearance. Unfortunately, no direct evidence is available to support this view. It is remarkable, though, that in studies related to the expression of naturally occurring protein S mutants, the levels of total protein S in the corresponding patients were higher than what would be expected from the in vitro expression studies. 17, 18 More specifically, levels of free protein S were severely reduced, whereas levels of C4BP␣␤-bound protein S were only mildly reduced in these patients. 17, 18 As such, these data are in support of the possibility that C4BP␣␤-bound protein S displays a longer survival in the circulation than free protein S.
One protein S variant that is consistently associated with reduced antigen levels is protein S-Heerlen, which occurs in Ϸ0.5% of the population. 20 Although, in particular, the levels of free protein S-Heerlen are decreased, 18, 22 total protein S levels are also slightly but significantly reduced. 18 The underlying mechanism of this phenomenon has remained unclear because expression studies using recombinant variants demonstrated that protein S-S460P is synthesized and secreted as efficiently as wt-protein S. 21 Thus, other mechanisms should be responsible for the low levels of protein S-Heerlen. We therefore applied our experimental mouse model to investigate the in vivo survival of free protein S-S460P. Our experiments using purified recombinant protein S-S460P clearly reveal that this mutant disappears from the circulation more rapidly than wt-protein S (Figure 3 ), resulting in a 3-fold shorter MRT (Table) . This demonstrates that the Ser460 to Pro substitution, per se, is associated with increased clearance and explains why levels of free protein S are reduced in individuals carrying the Heerlen polymorphism. Hence, increased clearance is a mechanism that contributes to the pathology of protein S deficiency.
The reason why protein S-S460P is cleared more rapidly remains to be determined, but it may be associated with mutation-induced conformational changes. Alternatively, it may be related to the absence of the carbohydrate chain at position Asn458. Irrespective of the exact mechanism, it should be noted that the increased clearance rate could be compensated partially in the presence of C4BP␣␤ (Figure 3 ). C4BP␣␤ interacts with several regions in the sex-hormonebinding-globulin-like domain, including the region 453 to 460, which encompasses the Asn458 glycosylation site and the Ser460Pro replacement. 39 This provides C4BP␣␤ the potential to mask mutation-induced alterations, allowing C4BP␣␤ to counteract the increased clearance. This would explain the near-normal levels of C4BP␣␤/protein S-Heerlen and offers a rationale for the observed Type III deficiency phenomenon.
